ArticleEClinicalMedicine2023

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.

Mairéad G McNamara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.